We recently published a list of 12 of the best selling medical stocks to buy now. In this article, let's take a look at other top selling places where CRISPR Therapeutics AG (NASDAQ: CRSP) sells the best and buy now.
Healthcare and expenditures are on the rise in the US. The Centers for Medicare & Medicaid Services reflects a 7.5% increase in the US, reflecting a 7.5% increase in US health costs in 2023, accounting for around 17.6% of the US economy in 2023 and an 17.4% increase since 2022. reported an increase. Two major drivers of this growth are the rise in private health insurance and Medicare.
Also read: 10 best-performing medical stocks so far in 2025 and the 10 most underrated small caps to invest.
As more and more US companies are seeking China to trade on the next promising molecule about the impact of tariffs on this ongoing trend, whether in the obesity or the cancer space, it is important in the healthcare industry. It is the subject of discussion. On February 7th, Versant Ventures Managing Director Carlo Rizzuto appeared on CNBC's “Fast Money” to discuss the impact of tariffs on healthcare. Rizzuto believed there were two ways that tariffs could affect the industry. The first is a product that has been innovated in China and innovated to the US or other markets. To understand how tariffs affect such trade processes, the industry needs to see how tariffs are actually structured in the market.
Second, and more specifically, China is a large center for contract research and manufacturing in the US medical industry. So anything that increases that cost can make the market situation even more difficult. The healthcare industry is already under pressure in terms of investor sentiment, and increasing costs won't help its function.
Speaking about the immeasurable role China plays in the Pharma and Healthcare space, Rizzuto said that the majority of healthcare companies use Chinese CROs or manufacturing partners in one way or another in the R&D process. So this is a very important part of how biotechnology or pharmaceutical companies operate in the country. This trend is widely and common, moving from the smallest to the largest.
Simply put, it is impossible for a healthcare company to reissue all of its externalized R&D and manufacturing to the United States. This is because the country does not have enough capacity to accommodate transfers. Therefore, it is very difficult to imagine how a re-bearing body of such a size would be done. The cost of carrying out this feat can be calculated linearly with the amount of customs duties applied.
The story continues
In depth into the dynamics of the industry, Rizzuto called the obesity space and the wider cardiac metabolic domain the biggest value creation opportunity in the industry's history. In the article on the 10 Best Drug Strains recently published, the Buy Now article discussed whether China is the next big thing in the pharmaceutical industry. This is an excerpt from the article.
“Large American pharmaceutical companies show clear trends that they have never seen before. They are increasingly searching for drugs in China. As reported on CNBC, Dealforma data According to 2024, approximately 30% of the major Pharma deals in 2024, including Chinese companies, have been contracted, with at least $50 million in 2024. This is almost 0% five years ago, from 20% the previous year. The surge in Chinese trade comes as US policymakers and President Donald Trump pursue protectionist policies for technology such as semiconductors and AI.
Using a stock screener, we have compiled a list of healthcare stocks that have experienced significant declines over the past year. Next, we selected 12 stocks with the best analysts' upward potential. We also added the number of hedge fund holders for these stocks as of the third quarter of 2024. Hedge fund sentiment data was sourced from the Insider Monkey database. This list is sorted in ascending order of analysts' likelihood of rising. All data is as of February 18, 2025.
Why do we care about what hedge funds do? The reason is simple. Our research shows that mimic the top stock picks of the best hedge funds can outperform the market. Quarterly Newsletter's strategy has chosen 14 small and large caps per quarter, returning 275% since May 2014, breaking the benchmark by 150 percentage points (see more here).
Why did CRISPR Therapeutics AG (CRSP) surge on Friday?
Cell-grown cells for the development of gene therapy and cell therapy.
Perfect year: -34.11%
Analyst Rise: 57.33%
Number of hedge fund holders: 27
CRISPR Therapeutics AG (NASDAQ: CRSP), headquartered in Zug, Switzerland, develops transformed gene-based drugs for serious diseases through its proprietary CRISPR/CAS9 platform. The CRISPR/CAS9 platform allows for accurate changes to genomic DNA by employing gene editing technology. The company's product portfolio spans treatment programs in a variety of disease areas, including oncology, rare diseases and regenerative medicine.
CRISPR Therapeutics AG (NASDAQ: CRSP) focuses on strategically moving its portfolio of clinical trials across autoimmunity, diabetes, oncology, and cardiovascular indications. The FDA approval and launch of Casgevy, a gene therapy to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in patients over the age of 12, has created considerable momentum for the company. CRISPR Therapeutics AG (NASDAQ: CRSP) has been approved by drug regulatory authorities in various countries around the world, including Canada, Switzerland, the UK and the European Union, and product launches are underway. The ongoing launch of the drug is gaining momentum continuously, and is expected to see a significant increase in the start of new cell patients collection in 2025. Over 50 certified treatment centers (ATCs) from Casgevy are being revitalized worldwide.
As of December 31, 2024, there is a strong balance sheet with approximately $1.9 billion in cash, cash equivalents and marketable securities. Therefore, supported by approved commercial products, a strong balance sheet and a rich pipeline, we are in a good position to expand our operations after 2025.
Overall, CRSP ranks number 10 on the list of the most sold medical stocks to buy now. We acknowledge the possibility of CRSP, but our belief is that AI stocks provide higher returns and hold a greater promise to do so within a shorter time frame. there is. If you're looking for AI stocks that are more promising than CRSP but are trading at less than five times the revenue, check out our report on the cheapest AI stocks.
Read next: Buy list of AI companies with market capitalizations under $2 billion 20 AI stocks now
Disclosure: None. This article was originally published on Insider Monkey.
